Healthcare Industry News: matrix metalloproteinase
News Release - May 2, 2007
PTC Therapeutics Announces Promotion of Neil Almstead to Senior Vice President of Chemistry and CMCSOUTH PLAINFIELD, N.J., May 2 (HSMN NewsFeed) -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post- transcriptional control processes, today announced the promotion of Neil Almstead to Senior Vice President of Chemistry and CMC, Chemistry Manufacturing and Controls.
"I am honored to be a part of a phenomenal team here at PTC," said Dr. Almstead. "From our early drug discovery efforts through to the clinic, we have an excellent track record of accomplishments. I look forward to working with Stuart and my other colleagues on the further clinical development of PTC124 and PTC299 as well as advancing our numerous other programs."
Dr. Almstead joined PTC from Procter & Gamble (P&G) where he was directly involved in the areas of inflammatory diseases and oncology. At P&G he was project leader for both the matrix metalloproteinase and Map kinase inhibitor projects. Dr. Almstead has coauthored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders, oncology and inflammatory diseases. After receiving his Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign under the direction of Professor Scott Denmark, Dr. Almstead was a postdoctoral associate at the University of Basel in Switzerland with Professor Bernd Giese.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small-molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, CV Therapeutics, and Schering-Plough.
Source: PTC Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.